OTSKF News and Press, Otsuka Holdings Co. Ltd. From 02/16/23

Otsuka Holdings Co., Ltd. ( OTCPK:OTSKF ): FY GAAP EPS of ¥246.99. Revenue of ¥1.74B (+16.8% Y/Y). For further details see: Otsuka Holdings Co., Ltd. GAAP EPS of ¥246.99, revenue of ¥1.74B

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...

Otsuka Holdings Co., Ltd. press release ( OTCPK:OTSKF ): Q3 GAAP EPS of ¥204.63. Revenue of ¥1.26B (+13.5% Y/Y). For further details see: Otsuka Holdings Co., Ltd. GAAP EPS of ¥204.63, revenue of ¥1.26B

The European Medicines Agency (EMA) accepted Astex Pharmaceuticals' application seeking approval for the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) as an initial treatment of adults with acute myeloid leukemia (AML) who are not eligible for standard induc...

Otsuka Holdings Co., Ltd. press release ( OTCPK:OTSKF ): Q2 Non-GAAP EPS of ¥128.54. Revenue of ¥814.31B. For further details see: Otsuka Holdings Co., Ltd. Non-GAAP EPS of ¥128.54, revenue of ¥814.31B

Potential M&A interest in Aurinia Pharmaceuticals ( NASDAQ: AUPH ) could be hampered -- at least in the short-term -- by a board's review of a patent related to the company's lupus drug Lupkynis (voclosporin), according to Cantor Fitzgerald. Shares are down 7% in l...

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired. Aurinia also disclosed that its chief commercial officer will be...

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...